文献速递肾小球疾病

抗PLA2R时代膜性肾病治疗临床试验设计:Nephcure研讨会报告

Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop.
PubMed 文献 · Kidney Int · 2025-03-14

原发性膜性肾病是成人肾病综合征常见病因,年发病率12例/百万。2009年发现PLA2R为疾病自身抗原,约75%患者可检出抗PLA2R抗体。2023年1月Nephcure Kidney International召开研讨会,讨论抗PLA2R抗体科学现状及其在膜性肾病药物开发项目中的整合考量,本报告记录该讨论内容。

要点

  • 原发性膜性肾病年发病率12例/百万,是成人肾病综合征常见病因。
  • 约75%原发性膜性肾病患者可检出抗PLA2R抗体。
  • 研讨会讨论将抗PLA2R抗体纳入膜性肾病药物开发项目的考量。

核心结论

  • 抗PLA2R抗体的发现为膜性肾病个体化管理提供机会,研讨会讨论了将其纳入药物开发项目的相关考量。

研究设计与样本

  • 2023年1月14日Nephcure Kidney International在弗吉尼亚州阿灵顿召开科学研讨会,本报告记录会议讨论内容。

主要发现

  • 原发性膜性肾病年总体发病率为12例/百万。
  • 约75%原发性膜性肾病患者可检出抗PLA2R抗体。
  • 2009年鉴定出M型磷脂酶A2受体1(PLA2R)为疾病自身抗原,此后较快鉴定出其他自身抗原。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year. Primary membranous nephropathy is an autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive until 2009 when the M-type phospholipase A2 receptor 1 (PLA2R) was identified as a disease autoantigen. This was followed relatively rapidly by identification of several other autoantigens. Autoantibodies against PLA2R are detectable in ≈75% of patients with primary membranous nephropathy. The discovery of circulating and deposited autoantibodies against PLA2R offers an opportunity in nephrology to personalize disease management. On January 14, 2023, Nephcure Kidney International convened a scientific workshop in Arlington, Virginia, to discuss the state of the science on autoantibodies against PLA2R and considerations related to the incorporation of autoantibodies against PLA2R in drug development programs for membranous nephropathy. The present report captures the discussion that occurred at the Membranous Nephropathy Scientific Workshop.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Prunotto M, Nachman PH, Gillespie BS, et al. Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop. Kidney Int. 2025. PMID: 40088237. doi:10.1016/j.kint.2024.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。